<DOC>
	<DOCNO>NCT01594268</DOCNO>
	<brief_summary>A prospective , open label study CERtican KIdney transplantation</brief_summary>
	<brief_title>A Prospective , Open Label Study CERtican KIdney Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion criterion : ( Each patient must meet following criterion . ) 1 . Males female age 2065 year inclusive ( Korean age ) schedule receive primary kidney transplant . 2 . Patients receive explanation study overview sign informed consent form study . 3. de novo patient go receive kidney transplant decease ( cold ischemic time ( CIT ) &lt; 36 hour ) , live unrelated related donor Exclusion criterion ( Any patient meet follow criterion able participate study . ) 1 . Multiorgan transplant recipient ( e.g . simultaneous kidneypancreas transplant ) patient previously receive organ transplant kidney transplant 2 . Patients schedule receive kidney transplant zeroantigen mismatch donor , bilateral kidney donor , nonheart beat donor donor age 60 year 3 . Patients avoid potential exposure everolimus due acute chronic severe allergy treatment patient hypersensitivity everolimus drug similar chemical class ( e.g . macrolides ) 4 . Class 1 PRA &gt; 30 % CDCbased assay Class 1 PRA &gt; 50 % flow cytometry EIA 5 . Recipients kidney ABOincompatible livedonor Tcell cross matchingpositive donor 6 . Thrombocytopenia &lt; 75,000/mm3 , absolute neutrophil count &lt; 1,500/mm3 , and/or leukopenia &lt; 4,000/mm3 7 . Severe hypercholesterolemia ( 350mg/dl ) hypertriglyceridemia ( &gt; 500mg/dl ) ( However , patient control hyperlipidemia eligible study . ) 8 . Use investigational drug 30 day enrollment study 9 . History malignancy organ system ( localize basal cell carcinoma skin ) , treat untreated , within past 5 year enrollment study , regardless whether evidence local recurrence metastases 10 . Pregnant nursing woman , woman childbearing potential plan pregnant consent select appropriate method birth control ( e.g . oral contraceptive , hormone implant , IUD , diaphragm barrier , condom , abstinence , etc . ) ( woman childbearing potential mean woman le 2 year postmenopausal hysterectomy surgical management , i.e . bilateral tubal ligation bilateral oophorectomy ) 11 . Presence surgery medical condition ( except current transplant ) may change absorption , distribution , metabolism , excretion investigational product investigator 's discretion and/or severe diarrhea , active gastrointestinal disease uncontrolled diabetes 12 . Patients HIV , HCV , HBV positive 13 . Recipients organ donor HBsAg , HCV , HIVpositive 14 . Evidence drug alcohol abuse 15 . Severe restrictive obstructive pulmonary disease 16 . Patients severe liver disease ( AST , ALT total bilirubin &gt; 2.5 time ULN include abnormal liver function test ) 17 . Patients severe systemic infection require continuous therapy may influence objective study investigator 's discretion 18 . Patients continuous treatment may lead clinically serious infection investigator 's discretion patient severe surgery complication problem continuous wind treatment 19 . Patients genetic problem include galactose intolerance , lapp lactase deficiency , glucosegalactose malabsorption</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>kidney transplant</keyword>
	<keyword>Certican</keyword>
</DOC>